Results for this period
Interim period (second quarter)1 January 2026–30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue increased due to stable sales in the Medical Business and the medical data platform business in the HealthTech Business. Operating income and ordinary income fell below the year-earlier levels because the HealthTech Business strategically increased staffing, mainly in consulting positions. Interim net income declined due to the recognition of approximately ¥100 million in losses on valuation of investment securities resulting from the impairment of shares in investee companies.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 June 2026 |
| Net Sales | ¥3,145 million (YoY +0.6%) |
| Operating profit | ¥888 million (YoY -7.0%) |
| Ordinary income | ¥922 million (YoY -6.4%) |
| Profit attributable to owners of the parent | ¥560 million (YoY -18.2%) |
| Net income per share | ¥22.96 |
| Equity ratio | End of the current fiscal period 81.7 / End of previous period 79.9 |
| Total assets | ¥6,921 million |
| Net assets | ¥5,683 million |
| Cash flows from operating activities | ¥1,303,765 thousand |
| Cash flows from investing activities | ¥-168,069 thousand |
| Cash flows from financing activities | ¥-343,315 thousand |
| Cash and cash equivalents at end of period | ¥2,351,266 thousand |
| Full-year earnings forecast | Net Sales ¥6,209 million (YoY +1.6%) / Operating profit ¥1,829 million (YoY +2.2%) / Ordinary income ¥1,889 million (YoY +2.6%) / Net income ¥1,302 million (YoY +3.6%) |
| Annual Dividend Forecast | ¥22 → ¥27 |
| Segment revenue | Healthcare business ¥2,908,009 thousand (YoY +1.8%), Public-sector business ¥172,812 thousand (YoY -29.1%), Healthtech business ¥64,593 thousand (YoY +150.2%) |
| Segment profit | Healthcare business ¥945,671 thousand (YoY +1.0%), Public-sector business ¥27,921 thousand (YoY -77.6%), Healthtech business ¥-85,101 thousand |
| Orders received and order backlog | Orders received ¥1,924,777 thousand / Order backlog ¥1,693,165 thousand |
| Depreciation and amortization | ¥19,186 thousand |
| Impairment loss | ¥106,964 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss ¥106,964 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person For analysts |
| Issued Shares at Period-End | 26,608,800 |
| Treasury Shares at Period-End | 2,184,279 |
| Factors Behind Changes in Business Performance | Revenue increased due to stable sales in the Medical Business and the medical data platform business in the HealthTech Business. Operating income and ordinary income fell below the year-earlier levels because the HealthTech Business strategically increased staffing, mainly in consulting positions. Interim net income declined due to the recognition of approximately ¥100 million in losses on valuation of investment securities resulting from the impairment of shares in investee companies. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased due to stable sales in the Medical Business and the medical data platform business in the HealthTech Business. On the earnings side, operating income and ordinary income declined because the HealthTech Business strategically increased staffing, mainly in consulting positions. Interim net income attributable to owners of the parent declined due to the recognition of approximately ¥100 million in impairment losses on investment securities resulting from the impairment of shares in investee companies.